Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
KRP203 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| KRP203 - 1.2 mg | EXPERIMENTAL | - |
| Placebo to KRP203 - 1.2 mg | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| KRP203 - 1.2mg | DRUG | - |
| Placebo to KRP203 - 1.2 mg | DRUG | - |
Inclusion Criteria: * Male and female patients,18 to 65 years of age inclusive, who have been defined as having SCLE based on the typical clinical picture and the characteristic histopathological features as described by Sontheimer et al. at least three months before study entry (screening) Exclus...
KRP203 is an investigational small molecule being studied for the treatment of subacute cutaneous lupus erythematosus, a form of lupus that affects the skin. It is being developed by Novartis AG and has completed a Phase 2 clinical trial.
KRP203 is a small molecule immunomodulator. Its specific molecular target has not been disclosed in available information. It is being investigated for its potential effects in subacute cutaneous lupus erythematosus, an autoimmune skin condition.
KRP203 is being developed by Novartis AG, a multinational pharmaceutical company listed on the New York Stock Exchange under the ticker symbol NVS. The drug is currently in clinical development for subacute cutaneous lupus erythematosus.
KRP203 is in Phase 2 clinical development. A Phase 2 trial for subacute cutaneous lupus erythematosus has been completed. The drug is investigational and has not been approved by regulatory authorities.
KRP203 has one completed Phase 2 clinical trial, registered as NCT01294774, titled 'Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus'. The trial enrolled 10 participants and was conducted in Germany, Greece, and Italy.